In this setting, Adaptive Advantage: ALT sustains telomere length despite high mitotic demand, allowing cancer cells to bypass replicative senescence; Oncogenic Diversity: Ongoing telomeric recombination generates chromosomal rearrangements and structural variations, which may activate oncogenes or disable tumor suppressors. This evidence concerns the gene GPT and cancer.